Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient

Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of “prime-boost” (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such...

Descripción completa

Detalles Bibliográficos
Autores principales: Michiels, Yves, Houhou-Fidouh, Nadhira, Collin, Gilles, Berger, Jérôme, Kohli, Evelyne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540857/
https://www.ncbi.nlm.nih.gov/pubmed/34696248
http://dx.doi.org/10.3390/vaccines9101140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540857/
https://www.ncbi.nlm.nih.gov/pubmed/34696248
http://dx.doi.org/10.3390/vaccines9101140

Ejemplares similares